Virtual
Event Title
CERSI Program Showcase
October 5, 2023
- Date:
- October 5, 2023
![CERSI Program Showcase on October 5, 2023](https://public4.pagefreezer.com:443/content/FDA/04-10-2023T15:54/https://www.fda.gov/files/styles/main_image_medium/public/CERSI_showcase_darkblue.jpg?itok=ir9mmu_R)
CERSI Program Showcase
October 5, 2023
9:00 AM-4:30 PM (Eastern Standard Time)
This event will include:
- Presentation from new Research Triangle CERSI
- Updates from existing CERSIs
- Research project presentations from selected topics in the Regulatory Science Framework
- Charge 1 - Modernize Development & Evaluation of FDA Regulated Products
- Charge 2 - Strengthen post-market surveillance and labeling of FDA-regulated products
- Charge 3 - Invigorate public health preparedness and response of FDA, Patients & Consumers
Please register for virtual attendance using the link below. After registering, you will receive a confirmation email containing information about joining the webinar.
The meeting will be recorded and available after the event.
Background
The Centers of Excellence in Regulatory Science and Innovation (CERSI) program led by the Office of Regulatory Science and Innovation (ORSI) promotes innovation in regulatory science through cutting-edge scientific research and information sharing opportunities that support FDA's regulatory science needs. The collaborations between CERSIs and FDA scientific experts target one or more of the focus areas in the Regulatory Science Framework. The current CERSIs were selected and awarded through a competitive process for a cooperative agreement. Renewal awards were made to University of Maryland, Johns Hopkins University, Yale University in joint effort with Mayo Clinic, and University of California at San Francisco (UCSF) in a joint effort with Stanford University (UCSF-Stanford). A new award was made to the University of North Carolina, Chapel Hill, in a partnership with Duke University, which will be called Research Triangle CERSI.
Agenda
Time | Topics | Speakers/Moderators |
---|---|---|
9:00 am - 9:30 am |
Introduction | Tina Morrison, PhD ORSI Director |
9:30 am - 9:40 am | Opening Remarks | Jacqueline O’Shaughnessy, Ph.D. Deputy Director Office of the Chief Scientist |
CERSI Highlights |
Moderator: Tina Morrison, PhD | |
9:40 am - 10:15 am | Research Triangle CERSI- University of North Carolina & Duke University | Paul Watkins, PhD; UNC Susan Halabi, PhD; Duke Univ. Robert Mentz, MD, Duke Univ. Ehsan Samei, MD, Duke Univ. |
10:15 am - 10:25 am | M-CERSI (University of Maryland) | James Polli, PhD William Bentley, PhD |
10:25 am - 10:35 am | JH-CERSI (Johns Hopkins University) | Caleb Alexander, MD |
10:35 am - 10:45 am | Yale-Mayo Clinic CERSI | Joseph Ross. MD; Yale University Molly Jeffery, PhD: Mayo Clinic |
10:45 am - 10:55 am | UCSF-Stanford CERSI | Russ Altman, MD, PhD; Stanford University |
10:55 am - 11:15 am | Q&A all CERSIs | Moderator: Tina Morrison, PhD |
Break | ||
Session 1 Charge 1- Modernize Development & Evaluation of FDA Regulated Products |
Moderator: Ruth Barratt, PhD; CDER | |
11:25 am - 11:45 am | Development of a precision oncology decision support platform to enhance genotype-driven clinical trial recruitment and decentralized personalized medicine approaches | Valsamo Anagnostou, MD, PhD; JHU Preeti Narayan, MD; CDER |
11:45 am - 12:05 pm | Multi-organ microphysiological systems for modeling clinical drug effects | Ishan Goswami, PhD; UC, Berkeley |
12:05 pm - 12:25 pm | Development, Implementation, and Evaluation of an Open Source Software to Support Patient-based Estimation of Clinically Meaningful Levels and Change Scores for Patient Reported Outcome Measures | Karon F. Cook, PhD; Feral Scholars Fraser Bocell, MEd, PhD; CDRH |
12:25 pm - 12:45 pm | Tissue Chips for Multipotent Stromal Cell Manufacturing | Ngan Huang, PhD; Stanford University Kyung Sung, PhD; CBER |
12:45 pm - 1:45 pm |
Lunch | |
Session 2 Charge 2- Strengthen post-market surveillance and labeling of FDA-regulated products |
Moderator: Brittany Caldwell, PhD, MBA; CDRH | |
1:45 pm – 2:05 pm |
Patient and provider informed labeling of AI/ML-Based Software to enable transparency and trust for cardiac monitoring and diagnostics | Barbara Barry, PhD; Mayo Clinic Aubrey Shick, MS; CDRH |
2:05 pm – 2:25 pm |
Assessment of Safety and Performance Issues with Extended Reality (XR) Tele-mentoring of an Image-Guided, Clinically Important Procedure | Matthew Johnson; University of Maryland Ryan Beams, PhD; CDRH |
2:25 pm – 2:45 pm |
An Electronic Approach for Post-Market Surveillance for Antimicrobial-Associated Adverse Events | Associated Adverse Events Jerald Cherian, MD, MHS; JHU Ramya Gopinath, MD; CDER |
2:45 pm - 3:05 pm |
Evaluate the application of machine learning algorithms to the management of postpartum hemorrhage Management | Moeun Son, MD; Yale University Kevin Dysart, MD; Nemours Kristie Baisden, DO; CDER |
3:05 pm – 3:15 pm |
Break | |
|
Session 3 Charge 3- Invigorate public health preparedness and response of FDA, Patients & Consumers |
Moderator: Emily Braunstein, PhD; CBER |
3:15 pm – 3:35 pm |
Improving Efficacy and Safety of Pathogen Inactivation Strategies for Platelet Transfusion | Magali Fontaine, MD, PhD; Univ. of Maryland Carlos Villa, MD, PhD; CBER |
3:35 pm – 3:55 pm |
Integrating patient and consumer-generated discursive data to inform and enhance FDA One Health Initiative communication strategies | Daniel Mullins, PhD; University of Maryland Christine Lee, PharmD, PhD; OMHHE |
3:55 pm – 4:15 pm |
Metabolism-based DDI and liver toxicity of drugs for COVID-19 treatment | Hongbing Wang, PhD; University of Maryland |
4:15 pm – 4:35 pm |
Trends in Opioid Use Among Patients with Cancer | Henry Park, MD, PhD; Yale University Catherine Lerro, MPH, PhD; OCE |
4:35pm – 4:40 pm |
Closing | Rebekah Zinn, PhD |